On November 10, 2025, Eli Lilly (LLY) stock closed at $966.64, up 4.57%, marking a new all-time high and reflecting strong investor enthusiasm[3]. The surge followed a series of analyst actions: Freedom Capital Markets downgraded LLY from Buy to Hold but raised its price target to $950, citing valuation concerns despite exceptional Q3 results, while Leerink Partners upgraded the stock to Outperform with a higher target[1][2][4]. Eli Lilly's Q3 revenue soared 54% year-over-year, driven by robust sales of diabetes and weight loss drugs, and the company raised its 2025 guidance for the second time this year[1]. The stock's sharp rise was attributed to these strong fundamentals and positive analyst sentiment, outweighing concerns about pricing pressures and formulary changes[1][2].